Clinical Trials

Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced…
Read More...

Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the successful…
Read More...

Navidea Biopharmaceuticals, Inc. a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced disappointing results of an exploratory…
Read More...

Neumora Therapeutics, Inc. announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive…
Read More...

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic…
Read More...

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with…
Read More...

PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and…
Read More...

Johnson & Johnson announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2…
Read More...

Repare Therapeutics Inc. announced that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40…
Read More...

Alcon announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the…
Read More...

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango…
Read More...

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos…
Read More...

GSK plc announced positive preliminary results from its phase III trial evaluating the immune response and safety of Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults…
Read More...

BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced on October 7th that its clinical trial application for BR105 Injection has received approval from the…
Read More...

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the US FDA has granted priority review…
Read More...

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key…
Read More...

AbbVie and Calibr announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas…
Read More...

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the initiation…
Read More...

TiumBio Co., Ltd. and Hansoh Pharmaceutical Group Co., Ltd. announced that the China National Medical Products Administration (NMPA) approved Hansoh's Investigational New Drug (IND)…
Read More...

Innovent Biologics, Inc. and RemeGen Co., Ltd. announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT…
Read More...